Catastrophic antiphospholipid syndrome following the introduction of rivaroxaban. (June 2020)

• Record Type: Journal Article
• Authors: Stammler, Romain; Legendre, Paul; Cacoub, Patrice; Blanche, Philippe; Piette, Jean -Charles; Costedoat -Chalumeau, Nathalie
• Is Part Of: Lupus. Volume 29:Number 7(2020)
• Page Start: 787
• Page End: 790
• Publication Date: 2020-06
• Subjects: Anticoagulants -- antiphospholipid syndrome -- catastrophic illness -- rivaroxaban -- thrombotic microangiopathies; Systemic lupus erythematosus -- Periodicals; 616.772005
• DOI: 10.1177/0961203320914363
• Languages: English
• ISSNs: 0961-2033

Abstract

Summary: Catastrophic antiphospholipid syndrome is the most severe complication of antiphospholipid syndrome. Vitamin K antagonists are the reference treatment for preventing relapsing thrombotic complications in patients with antiphospholipid syndrome. Direct oral anticoagulants are nonetheless sometimes used in this setting. We report two cases of women who were triple-positive for antiphospholipid antibodies and developed catastrophic antiphospholipid syndrome in the week after the introduction of rivaroxaban. The first patient, who had had a previous thrombotic event, had multiorgan failure 3 days after vitamin K antagonists was replaced by rivaroxaban, and the second developed a similar clinical presentation 7 days after introduction of the same treatment. Both catastrophic antiphospholipid syndrome episodes were successfully treated with heparin followed by vitamin K antagonists, corticosteroids, and plasmapheresis. These two cases highlight for the inefficacy of rivaroxaban preventing severe thrombotic events such as catastrophic antiphospholipid syndrome and thus provide further support for recommendations that vitamin K antagonists must remain the reference anticoagulant in patients with triple-positive antiphospholipid antibodies.